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ABSTRACT: Despite the success that drug-eluting stents (DESs) have achieved for minimizing in-stent restenosis (ISR), the antirestenotic
agents used in DES have been implicated in delayed endothelial healing and impairment of endothelial functions. Cenderitide (CD-NP)
is a novel antiproliferation chimeric peptide of semiendothelial origin; thus, this paper aims to demonstrate the selectivity aspect of this
new peptide via in vitro evaluation on key players in ISR—smooth muscle cells (SMCs) and endothelial cells. The microbicinchoninic acid
protein assay was used to investigate the CD-NP release from films and stents. Cenderitide-containing films blended with poly(ethylene
glycol) and its copolymer exhibited higher release kinetics compared with neat poly(ε-caprolactone) (PCL) formulation. Cenderitide-eluting
stents (CES) was produced by coating bare metallic stents with CD-NP entrapped PCL using an ultrasonic spray coater. The investigation
of CD-NP on in vitro cells revealed that CD-NP inhibits human coronary smooth muscle cells (HCaSMCs) proliferation but exhibits no
effects on human umbilical vein endothelial cells (HUVECs) proliferation. Moreover, CD-NP released up to 7 days displayed inhibitory
effects on SMCs proliferation. The CES produced in this work shows that the released CD-NP inhibits HCaSMCs proliferation but did not
hamper HUVECs proliferation in vitro, suggesting that it has potential to reduce ISR without retarding the endothelialization healing in
vivo. C© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3631–3640, 2014
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INTRODUCTION
Cardiovascular disease is the number one cause of death in
the world1; in fact, 70% of hospitalizations are a resultant
of artery occlusion.2 To date, the use of immunosuppressive
agents such as paclitaxel and sirolimus in first-generation drug-
eluting stent (DES) successfully overcame stenosis and sig-
nificantly reduced the incidence of in-stent restenosis (ISR)
in stented segments by inhibiting the proliferation and mi-
gration of smooth muscle cells (SMCs) proliferation.3–5 How-
ever, amid the successful suppression of neointimal prolifera-
tion, the presence of these antiproliferative drugs in the tissue
may cause delay in the endothelial coverage and healing. In
one recent study, paclitaxel or rapamycin were found to up-
regulate antifrinolytic factor in human endothelial gene ex-
pression, resulting in the prothrombotic effects in DES.6 For
the last decades, DES-related work had been largely dedicated
to addressing ISR reduction and relatively less consideration
had been given to the initial damage of the endothelial lining
from the mechanical deployment of the DES and long-term de-
lay in endothelial healing as a resultant of antiproliferative
agents eluted from the DES. From reports, it is now evident
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that DES delayed healing, particularly from first-generation
DESs have significantly increased the risk of late-stage stent
thrombosis (LST) that is often fatal.7–10 The damaged endothe-
lial lining exposes the subintimal layer and this stimulates
the activation of platelets where a plethora of chemotactic and
mitogenic growth factors are being released. There is an ur-
gent need to address the issue of delayed endothelial heal-
ing and yet maintain a delicate balance between inhibition of
SMCs and enabling reendothelization of damaged endothelial
lining.
In the last 10 years, there have been escalating research
effort on the use of natriuretic peptide (NP) as therapeutic
agents11–14 in place of synthetic drugs. In particular, the c-
type NP (CNP) is a potent vasodilator and anti-inflammatory
agent.15–18 In rabbits study,19 continuous infusion of CNP post-
balloon catheter injury resulted in suppressed neointima for-
mation. However, the short half-life of CNP and lack of car-
diorenal functions limits its utility in disease states requir-
ing chronic administration, such as coronary artery disease
(CAD). CD-NP, developed by the Mayo Clinic,20 is a hybrid
of native CNP from human and a C-terminus isolated from
the dendroapis NP found in the venom of the green mamba.
The addition of the C-terminus tail enhanced the resistance
to proteolysis, resulting in increased half-life and prolonged
biological actions.21 Furthermore, the C-terminus tail equips
CD-NP with cardio-protective abilities to regulate natriuresis
and diuresis.12,14,21 CD-NP originates from endothelial origin
CNP; hence, we believe it is partial endothelial in nature. We
postulate that its semiendothelial nature and antiproliferative
properties of CD-NPmakes it a potential cardio agent for the in-
hibition of SMCs proliferation without compromising endothe-
lial healing.
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Currently, CD-NP is undergoing initial evaluation in hu-
mans by Mayo Clinic to address ventricular remodeling. Our
previous work have also demonstrated that controlled release
of CD-NP from films and patches sustained the suppression
of human cardiac fibroblast proliferation for cardiac remodel-
ing indication.22 However, its utility as an antirestenotic com-
pound have not yet been tested. Hence, in this work, we set out
to elucidate CD-NP’s selectivity in cell inhibition. We believe
that if CD-NP could selectively inhibit SMC proliferation and
yet not compromise endothelial healing, it could potentially
replace synthetic immunosuppressant and be used for treat-
ment in occluded vessels. In the treatment of occluded vessels,
continuous supply of antiproliferative agents is crucial for ef-
fective suppression of neointima proliferation over time; hence,
to maximize the potential of CD-NP for this indication, we aim
to develop a cenderitide-eluting stent (CES). CES could serve
as a local delivery system, providing cenderitide in a sustained
and direct manner to the site of injury. Additionally, encapsu-
lating CD-NP within the polymer matrix overcomes the issue
of CD-NP clearance, which also reduces unnecessary wastage.
In exploring the feasibility of developing such systems, thin
films were first used as screening tools to determine the release
kinetics and subsequently translated into the development of
CES. Biocompatible polymers poly(g-caprolactone) (PCL) was
selected as matrix for entrapment in this work because of its
biodegradability and biocompatibility.23,24 In this paper, we also
focus on elucidating the retention of bioactivity of CD-NP re-
leased from formulations. Finally, we developed CD-NP-coated
stents with suitable release profiles and characteristics for fur-
ther studies.
MATERIALS AND METHODS
Materials
CD-NP was obtained from American Peptide Company, CA,
USA. PCL (Mn: 80,000 g/mol) (Sigma–Aldrich, MO, USA), PEG
(Mw: 2000 g/mol) (Merck-Schuchardt, Hohenbrunn, Germany),
and copolymer PCL (1.5k)–PEG (5k) (Advanced Polymer Mate-
rials Inc., Que´bec, Canada) were used as received. Phosphate
buffer solution (PBS, pH 7.4) was obtained from OHME Scien-
tific, Singapore.
Film Preparation
The polymer solution was prepared by dissolving PCL pellets in
DCM (0.18 g/mL). The peptide solutionwas prepared by dissolv-
ing CD-NP in ethanol. The two solutions were mixed and sol-
vent cast. For formulations containing excipients, weight per-
centage of PEG and copolymer were added to the solution prior
to casting. The cast film was left in room temperature ambience
overnight and transferred to the 37◦C vacuum oven for 7 days.
The thermogravimetric analyzer (TA Instruments Q500; TA
Instruments, Research Instruments Pte Ltd, Singapore) was
used to verify residual solvent in films (<0.5, wt %). The thick-
nesses of fabricated films were 0.045 ± 0.005 mm (Elcometer
456, Elcometer (Asia) Pte Ltd, Singapore).
In Vitro Films Release Study
Samples prepared in triplicate were immersed in PBS and re-
plenished at predetermined time points. The amount of peptide
released was detected using the microbicinchoninic acid pro-
tein assay (Pierce, Thermo Fisher Scientific Inc., MA, USA) us-
ing the UV–Vis spectrophotometer UV-2501 (Shimadzu Corp,
Kyoto, Japan).
In Vitro Degradation Study
The films underwent similar process described in In Vitro Films
Release Study. At predetermined time points, samples were
rinsed with deionized water and dried in 37◦C vacuum oven
prior to characterization. The molecular mass was measured
using the gel permeability chromatograph Agilent Series 1100
(Agilent Technologies, CA, USA ), and the mass loss was calcu-
lated by taking the difference of the initial mass and the final
mass of the films over the initial mass.
Morphological Examination
Samples were gold sputtered under argon atmosphere for 20 s.
Surface morphology was observed with the scanning electron
microscopy (SEM) AS Jeol 6360 (JEOL Ltd, Tokyo, Japan) at
3 kV.
In Vitro Cell Culture
Human coronary smooth muscle cells and human umbilical
vein endothelial cells (HUVECs) were purchased from Lonza
Group, Basel, Switzerland. HCaSMCs were grown and main-
tained using the SmGM-2R© medium and 5% of fetal bovine
serum (FBS). Only cells from passages 3 to 6 were used for
this study. HUVECs were maintained using EGM-2R© medium
(Lonza) and 2% FBS. Only cells from passage 6 were used for
this study. All cells were grown in atmosphere 5% CO2 at 37◦C
incubator.
Cell Proliferation
The proliferation rate of HCaSMCs and HUVECs was investi-
gated using the bromo-2′-deoxyuridine (BrdU) assay (Roche).
Eight-thousand cells were seeded in 96-well plate for 24 h.
Cells underwent serum deprivation for 24 h to induce quies-
cent. Quiescent cells were incubated with CD-NP and CD-NP
was released from formulation for 4 h along with controls. Next,
cells were BrdU labeled for 24 h and tested in accordance with
the manufacturer’s protocol. The relative proliferation rates of
investigated groups were compared with positive controls of
SmGM-2R© or EGM-2R© and negative controls were their respec-
tive mediums without the addition of FBS. Relative prolifera-
tive value of control groups were set as 1. All treatment groups
were normalized to positive control group.
Detection of 3′5′ Cyclic Guanosine Monophospate
Eight-thousand cells were seeded in 48-well plate for 24 h.
Cells were incubated with CD-NP in PBS (without magne-
sium and calcium) containing 10 mM of 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid, 0.1% FBS, and 0.5 mM 1-
methyl-3-isobutyl xanthine at 37◦C for 30 min. Cells were
tested using the 3′5′ cyclic guanosine monophosphate (cGMP)
assay (GE Health) in accordance with the manufacturer’s pro-
tocol.
Coated Stent Preparation
The stents used in this study are closed cell design cobalt–
chromium stents with strut dimensions 0.075 × 0.080 mm2
(W × T) (Fortimedix B.V., Nuth, Netherlands). Bare metallic
Co–Cr stents were cleaned by immersing in acetone, ethanol,
and distilled water for ultrasonic cleaning for 20 min each and
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dried in 60◦C vacuum oven overnight. The MedicoatTM (Sono-
Tek Corporation, NY, USA) was used to spray the coat stents
used in this study. Table 1A and 1B give a summary of the film
and stents formulations and CD-NP loading, respectively.
In Vitro Stents Release Study
Coated stents were prepared in triplicate. The amount of pep-
tide released was detected using the method described in sec-
tion In Vitro Films Release Study.
Statistical Analysis
Results are presented in mean ± SD, unless otherwise stated.
For cell culture studies, each experiment was performed in trip-
licate in three separate assays. Statistical analysis was carried
out with the Origin 8.0 and GraphPad Prism 5.0. Values were
analyzed by one-way analysis of variance (ANOVA) followed by
Tukey’s test; p < 0.05 is denoted as statistically significant.
RESULTS
In Vitro Release from Films
Figure 1 shows the release profiles of CD-NP from PCL and
PCL with excipient-addition films. The results show that the
release of CD-NP fromneat PCLhad the lowest initial release of
20.4% and final release of 61.1% by 30 days. An increase in ini-
tial release of 26.4% and 66.6% from formulations with addition
of 5% and 10% PEG, respectively, was observed. The formula-
tions with addition of copolymer resulted in more pronounced
initial release. In 5% and 10% copolymer-addition formulation,
peptide from films was released completely within 18 days and
6 h, respectively.
In Vitro Degradation Study
In Figure 2a, the molecular mass study carried out over 30 days
showed no significant change for both the PCL and excipient-
added formulations. In Figure 2b, the percentage mass loss
recorded for PCL was 2.44 ± 0.05% by 30 days. The films with
addition of PEG displayed higher mass loss of 4.68 ± 0.43%
and 10.10 ± 0.30% for 5% and 10% PEG addition, respectively.
Similar mass loss trends were observed in films with copoly-
Figure 1. Accumulated release profiles of 1% CD-NP-loaded films ac-
cording to the addition of poly(ethylene glycol) PEG and copolymer PCL
(1.5k)–PEG (5k). All release sustained for 30 days except for films with
copolymer addition, where early complete release by 18 days and 6 h
time point was observed in 5% and 10% copolymer-addition formula-
tions, respectively.
mers addition, where 5% and 10% copolymer addition experi-
enced 3.97 ± 0.49% and 7.91 ± 0.41% mass loss, respectively.
It was observed that increase in mass loss corresponded to the
amounts of PEG and copolymer added.
Figure 3 shows the surface morphology of films at 0- and
30-day time point. Figures 3a–3c show films with addition
of PEG and copolymer appearing slightly more porous com-
pared with the PCL formulation. After 30 days of immersion,
films maintained their integrity (Figs. 3d–3f). The absence of
degradation in films corresponded to the molecular mass data
Table 1. Summary of the film and stents formulations
A. Films
Sample Name Materials Composition CD-NP Loading (%)
F-PCL 100% PCL 1
F-5% PEG 95% PCL + 5% PEG 1
F-10% PEG 90% PCL + 10% PEG 1
F-5% 1.5k–5k 95% PCL + 5% PCL(1.5k)–PEG(5k) copolymer 1
F-10% 1.5k–5k 90% PCL + 10% PCL(1.5k)–PEG(5k) copolymer 1
B. Stents
Sample Name Materials Composition CD-NP Loading (%) Weight of Coating (:g) Weight of CD-NP (:g)/Stent
BMS Cobalt–Chromium Stent
S-PCL BMS + 100% PCL 10 378 ± 15 39
S-5% PEG BMS + 95% PCL + 5% PEG 10 379 ± 24 42
S-10% PEG BMS + 90% PCL + 10% PEG 10 361 ± 11 38
S-5% 1.5k–5k BMS + 95% PCL + 5% PCL(1.5k)–PEG(5k) copolymer 10 355 ± 7 37
S-10% 1.5k–5k BMS + 90% PCL + 10% PCL(1.5k)–PEG(5k) copolymer 10 375 ± 3 38
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Figure 2. Molecular mass and mass loss of CD-NP-loaded films. (a) Molecular mass and (b) mass loss of CD-NP-loaded films according to
addition of PEG and copolymer PCL (1.5k)–PEG (5k) over 30 days.
Figure 3. Surface morphology of films loaded with CD-NP. SEM micrograph of 1% CD-NP-loaded PCL film, 1% CD-NP 10% PEG-loaded PCL
film, and 1% CD-NP 10% copolymer PCL (1.5k)–PEG (5k)-loaded PCL film on day 0 (a, b, and c) and after day 30 release (d, e, and f) in respective
order.
(Fig. 2a). In addition, the PCL with PEG addition formulations
were selected for the rest of the studies, because of the reason-
able initial burst and sustained release profile.
In Vitro Effects of CD-NP on HCaSMCs and HUVECs
As SMCs inhibition is the main factor in mitigating ISR, we
carried out in vitro studies to evaluate the inhibitory effects of
CD-NP on HCaSMCs. From literature, effective NP concentra-
tions have been reported in molar concentrations between 10−9
M and 10−5 M, which is 0.00037 (10−9 M)–37 :g/mL (10−5 M).
Figure 4a shows the proliferation rate of HCaSMCs upon addi-
tion of CD-NP in concentrations of 37, 0.37, and 0.0037 :g/mL
compared with the control. The DNA synthesis in HCaSMC
was suppressed by CD-NP, where inhibition occurred at doses
between 37 and 0.0037 :g/mL but beyond 0.0000037 :g/mL
inhibition was ineffective (not shown). The relative prolifera-
tion rates in CD-NP treatment groups were 0.82–0.86. Using
ANOVA, there was no significant dose dependency among con-
centrations of 37, 0.37, and 0.0037 :g/mL. Figure 4b shows the
relative proliferation rates of HUVEC after the addition of CD-
NP solution in concentrations of 37, 0.37, and 0.0037 :g/mL
compared with the control. The relative proliferation rates of
CD-NP treatment groups fell in the range of 0.98–0.99. CD-NP
exhibited no proliferative or inhibitory effects on HUVECs.
Figures 4c and 4d present the effect of CD-NP on the pro-
duction of cGMP in HCaSMCs and HUVECs, respectively. For
both cell types, the addition of CD-NP resulted in elevated
cGMP compared with control, implying that CD-NP elicits
particulate guanylyl cyclase (GC) receptor activation. The ad-
dition of CD-NP at concentrations of 37 :g/mL, the highest
concentration studied, produced more than two times cGMP
amounts compared with the control in HCaSMCs and approx-
imately five times more cGMP in HUVECs. There appears
to be a dose-dependent relationship between CD-NP concen-
tration and cGMP levels (p < 0.05) for both HCaSMCs and
HUVECs.
Bioactivity Study of Encapsulated and Released CD-NP
The cGMP assay was carried out to verify whether encap-
sulated CD-NP retained the ability to elevate cGMP alike
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Figure 4. CD-NP’s effect on HCaSMCs and HUVECs. Effects of addition of CD-NP on the relative proliferation in (a) HCaSMCs and (b)
HUVECs measured via colorimetric BrdU uptake normalized to control and (cGMP generation in (c) HCaSMCs and (d) HUVECs induced by
different CD-NP concentration; *p < 0.05.
nonencapsulated CD-NP. Figure 5a shows the cGMP levels pro-
duced by the CD-NP released from the different polymer for-
mulations compared with the control group. Both the PCL for-
mulation and PEG addition formulations showed statistically
significant production of cGMP compared with the control. Al-
though the degree of bioactivity could not be quantified, the
elevated production of cGMP implied that the released peptide
retained bioactivity.
To investigate the effects of released CD-NP on HCaSMCs,
CD-NP released at 1st, 3rd, and 7th day time points were
tested. The relative proliferation of HCaSMCs is shown in
Figure 5b. The encapsulated peptide (1st, 3rd, and 7th day)
Figure 5. Effects of released CD-NP on HCaSMCs. (a) cGMP generation in HCaSMCs induced by CD-NP released from different CD-NP-loaded
formulation, *p< 0.05 compared with control and (b) relative proliferation of CD-NP released from different CD-NP-loaded formulation (released
in 1 day, 3 days, and 7days) in HCaSMCs via BrdU; *p < 0.05.
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suppressed DNA synthesis compared with the control in a sta-
tistically significant manner (p < 0.05), indicating that the
encapsulated peptide retained inhibitory capability. The in-
hibitory effect between different formulations was compared
and there was no statistical significance between the groups,
suggesting that PEG addition in this work neither enhanced
nor decreased the inhibitory effects. Also, the inhibitory effect
of peptide released at different time points was compared, and
the absences of statistical significance suggest that CD-NP in-
hibitory effect did not deteriorate over time.
Characterization of Stents
Figures 6a–6c show the SEM micrograph of coated stents from
PCL and formulations with the addition of 5% and 10% PEG,
respectively. Overall, all formulations had uniform and smooth
surface coatings. There were no visible cracks between struts or
signs of peptide aggregation. The addition of 10% PEG results
in slightly dimpled morphology. Figure 6d shows the SEM of
the stent before angioplasty balloon expansion, and Figure 6e
shows the SEM of stent after angioplasty balloon expansion.
Expanding the stents did not result in observable cracks or
coating delamination, signifying that the stents produced were
able to withstand compressive and tensile strains from stents
expansion. To measure the coating thickness, the coating sur-
face was intentionally scratched with a sharp blade. Figure 6f
shows the thickness (15.69 ± 0.72 :m) of the coating measured
under SEM.
In Vitro Release from Stents
Figure 7a plots the cumulative peptide release from stents for-
mulation with and without the addition of PEG. The PCL for-
mulations observed a 3% initial release (24 h), whereas the
addition of 5% and 10% PEG increased the initial release of
CD-NP to 18% and 26%, respectively. This indicates that pep-
tide release is associated to the amount of excipient in the PCL.
Figure 7b shows the amount of peptide released. The PCL for-
mulation displayed consistent release throughout the 30 days,
releasing approximately 0.33 :g daily. PEG formulations dis-
played higher amount release, particularly on the 1st day. Fol-
lowing the burst release (24 h), 5% PEG and 10% PEG formu-
lations released 0.40 and 0.50 :g daily.
To compare the amount of CD-NP released from the stents
and films, the cumulative peptide released from PCL and PCL
with PEG-addition films were replotted in Figure 7c, and the
daily release was plotted in Figure 7d. The cumulative trend of
CD-NP released from the stents is similar to that in the films.
In Figure 7d, the PCL formulation released 1.86 ± 2.04 :g over
30 days, whereas 5% PEG and 10% PEG formulations observed
2.43 ± 0.97 and 2.24 ± 2.15 :g between day 2 and day 30 post
its burst release.
DISCUSSION
For patients with CAD, performing a percutaneous coronary
intervention procedure accompanied with a DES serves as me-
chanical means to patent the vessel, whereas its ability to
elute antiproliferative drugs concomitantly restrains the neoin-
tima proliferation. However, the deployment of DES would
inevitably injure the endothelial layer and the presence of
immunosuppressive drugs eluted into the tissue halts the grat-
ifying outcomes of DES because of the nonselectivity of the
drug for SMCs and endothelial cells (ECs), resulting in incom-
plete or delayed endothelialization of the vessel.3,4,9 The lack of
adequate healing gives rise to LST and ISR post angioplasty,
which prolongs the use of dual antiplatelet therapy in stented
patients and in some cases exacerbating to fatal LST.
The current study sought to develop a novel peptide eluting
stent incorporating designer peptide, CD-NP, which we postu-
late would inhibit neointima hyperplasia without compromis-
ing the endothelization of the vessel because of its endothelial
origin. The study was conducted in three successive stages. In
the first stage, we investigated the encapsulation and release
of CD-NP from films. In the second stage, we verified our pos-
tulation of CD-NP’s cell discriminatory property. The outcome
of the in vitro cell study demonstrated that CD-NP inhibited
HCaSMCs but did not affect the proliferation of HUVECs. In
the final stage, we verified the bioactivity of CD-NP encapsu-
lated in films and proceed to develop CES.
Figure 6. Surface morphology of CD-NP-loaded coated stents. SEM micrograph of 10% CD-NP-loaded stent coating of (a) PCL formulation,
(b) 10% addition of PEG, (c) 10% addition of copolymer PCL (1.5k)–PEG (5k); intact coating of CD-NP-loaded stent (d) before and (e) after
expansion; and (f) sectioned away stents coating.
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Figure 7. The comparison of CD-NP accumulated and daily release from between the stents (a and b) and films (c and d).
The therapeutic dose is critical in determining an efficacious
or adverse outcome; hence, it is important to understand the
peptide release kinetics andmechanism. In CD-NP-loaded neat
PCL films, a two phase release consisting of an initial burst
release followed by subsequent release was observed till 30
days. The initial burst release is likely because of the disso-
lution of peptide near the surface of the films, whereas the
subsequent release could be attributed to the diffusion of the
peptide from the polymer. Our molecular mass study showed
an absence of polymer degradation, which is expected as PCL
takes approximately 2–4 years for complete degradation.25,26
PCL displayed slow release kinetics because of the present of
high-crystalline domains that inhibits the water penetration
into the segment25; hence, the approach of adding excipients
was adopted. Our study showed that the addition of hydrophilic
excipient PEG resulted in a corresponding increase in the ini-
tial and final release. This observation could be attributed to
the physical changes in the matrix upon the addition of these
excipients.27–31 The SEM micrograph of films with PEG ad-
dition had observable pores on the surface of films, suggest-
ing that the formation of microcavities provided alternative
pathways for the peptides to exit. Furthermore, the faster pep-
tide release is likely associated to the peptides leaching out
along with the excipients. This postulation was further sup-
ported by the correlation between the mass loss and peptide
release results. Three-dimensional visual evidence of colocal-
ization of protein and hydrophilic excipients within films was
also reported.29 In this work, we also examined an amphiphilic
excipient copolymer PCL–PEG. However, the copolymers addi-
tion formulations fell short in achieving the desired sustained
release. In 5% and 10% copolymer-addition formulation, pep-
tide from films was released completely within 18 days and 6 h.
The rapid CD-NP release from copolymer-addition formulation
was not expected and this seemed to suggest that CD-NP in
copolymer formulations was distributed near the surface of the
films, possibly because of severe phase separation between the
hydrophilic and hydrophobic phases in the system.
The implantation of stent induces acute local inflamma-
tion, which induces migration and proliferation of SMCs lead-
ing to ISR. In our study, CD-NP in the concentration range
of 0.0037–37 :g/mL showed nondose-dependent inhibition on
SMCs proliferation. The suppressive capability of NPs had been
attributed to the elevation of intracellular cGMP,19,32 which is
activated by NPs binding with particulate GC receptors.12,14
In our study, CD-NP elicited cGMP production in a dose-
dependent manner in a similar manner like native NPs.12,14
However, the lack of correlation between the stimulation of
cGMP production and the inhibition of DNA synthesis suggest
that CD-NP’s inhibitory effects observed in SMCs might not
be solely because of the activation of GC receptors.33 Apart
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from inhibiting SMCs proliferation, ensuring unperturbed en-
dothelium regeneration is crucial to avert further progression of
ISR and LST. Endothelium is an important vascular component
that regulates the synthesis of growth factors, nitric oxide, and
protein matrixes.9 Our proliferation studies showed that CD-
NP did not inhibit the growth of ECs, suggesting that CD-NP
displayed cell-type discrimination inhibition. From the litera-
ture, native CNP has been reported to mediate the inhibition
of SMCs but promotes the proliferation of HUVECs.14,19,32,34 In
SMCs, CNP mediates inhibition via NPR-C activation (cGMP
production) and ERK 1/2 phosphorylation. ERK 1/2 in SMCs
triggers the expression of p21waf1/cip1 and p27kip1 expres-
sion, thereby preventing cell cycle progression and prolifera-
tion. On the contrary, CNP induces cell proliferation in HUVEC
via NPR-C activation and increase in ERK 1/2 and Akt activa-
tion. The activation results in augmenting cyclinD1 expression,
which facilitates cell cycle progression. Therefore, CNP-induced
cGMP regulates cell cycle protein expression and hence prolif-
eration differently in SMCs and HUVEC. As CD-NP and CNP
are similar in structure, we believe that the cell discrimina-
tion effects observed in CD-NP may be similar to the mecha-
nisms of CNP. However, further studies need to be carried out
to confirm this. Figure 8 illustrates how cell-type discrimina-
tion inhibition of CD-NP makes it superior compared with the
immunosuppressive drugs typically used in DES.
Very often, manufacturing process causes proteins and pep-
tides to undergo unintentional alteration, resulting in decline
or loss of pharmacological functions and effects. Moreover,
there are stringent structural requirements for the NP to be
bioactive.34 Our study shows that CD-NP released from all for-
mulations elicited elevation of cGMP, implying that bioactivity
was retained. From the SMCs inhibition studies, CD-NP re-
leased up to 7 days from formulations with and without PEG
addition displayed inhibitory effects on SMCs. The addition
of PEG has been reported to aid in retention of bioactivity
by protecting proteins and peptides from exposure of organic
solvents.35,36 We could not verify that PEG addition had en-
hancing effects to bioactivity retention. But we confirmed that
there is no loss of bioactivity because of the addition of PEG,
which implies that the addition of PEG could be used as ameans
to tailor release profiles without compromising bioactivity.
Poststenting rapid proliferation of SMCs occurs until 28
days; hence, a sustained delivery of antiproliferative up to 28
days is required to effectively counter ISR.7,9,10 From the film
release study, we learnt that neat PCL and formulations with
5% and 10% additions of PEG were able to give low, medium,
and high peptide release profiles up to 30 days. Thus, these
three formulations were selected for stents development. The
stent coatings produced by ultrasonic spray coating yielded uni-
form and smooth surface and the absence of delamination was
verified by pre- and postexpansion studies. Overall, the stents
formulations observed similar release trends as the film formu-
lations. The addition of PEG observed an increased in peptide
release for both films and stents that was expected.37,38 We
believe that the release from the PEG formulations followed
the “colocalization model,”29,39 where peptide colocalized with
hydrophilic excipients release along with the efflux of the ex-
cipients. The subsequent release of the peptide is dependent on
the leaching rates of the excipients and the rate of diffusion of
peptide out of the films and stents. Although, a slightly lower
peptide cumulative release was observed in stents formulations
compared with the films formulations. The difference observed
could be attributed to the difference in the peptide distribution
in the films and stents, given the faster the drying process in
spray-coated stents than film casting, more uniformity in pep-
tide distribution throughout the coating is expected compared
with the films. In addition, the dense surface of coated stent
versus porous surface of films might have also resulted in the
Figure 8. Illustration of cellular effects of immunosuppressive drugs from DES and CD-NP from CES.
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difference. The daily CD-NP release from 1% loaded films and
10% loaded CES was compared and found to be similar. This
implies that a comparable in vitro cell effect is expected from
the stents and films.
Our study shows that CD-NP is effective in inhibiting SMCs
proliferation without hampering ECs proliferation and the
achievement of sustained controlled release up to 30 days in
coated CES. However, the main limitation of this study is that
only in vitro evaluation was carried out. For further clinical
consideration, it is essential to consider its in vivo performance.
Hence, an animal study of CES is currently underway to inves-
tigate the effect of sustained-release CD-NP on the SMCs and
ECs in vivo.
CONCLUSIONS
In this study, we proved that partial endothelial origin CD-
NP effectively inhibited SMCs proliferation, but did not ham-
per HUVECs proliferation. We have also attained sustained
release from films and stents and manipulate its rate of release
by blending with PEG and copolymer. CD-NP has never been
tested for ISR indication; hence, this study is essential before
proceeding to in vivo evaluation. It is clear that CES has the
potential to replace currently used DESs.
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